NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Grifols SA GRFS
10 fiscal years on record · EUR · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
€7.2B
▲ 9.4% vs FY2023
EPS · FY24
€0.23
Dividend / sh · FY24
—
Payout · FY24
1%
ROE · FY24
2.8%
Net margin · FY24
2.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 7.2B
Revenue, FY2024 · full 10-year series below
Revenue
Net income
2 cents of every revenue dollar became profit this year.
Per share
EUR 0.23
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
2.8%
Return on equity, FY2024
ROE
Operating margin16.5%
Net margin2.2%
Return on assets0.7%
Each EUR of equity produced 3 cents of profit this year.
Returned to shareholders
EUR 962,000.00
returned in FY2024 · dividends + net buybacks
Dividends paidEUR 962,000.00
Net buybacks—
Share of profit0.6%
Consecutive raises—
EUR 962,000.00 in dividends — 1% of the year's profit went back to shareholders.
Growth
+7.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+13.5%
+7.2%
Net income
−6.0%
−24.2%
EPS, diluted
−6.3%
−24.0%
Returned to shareholders
−86.4%
−66.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 21.4B
total assets, end of FY2024
Total assetsEUR 21.4B
EquityEUR 5.9B
CashEUR 979.8M
Current ratio2.66×
Equity funds 27% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue €B
7.2
6.6
6.1
4.9
5.3
5.1
4.5
4.3
4.0
3.9
Operating income €B
1.2
0.8
0.8
0.6
1.0
1.1
1.0
1.0
0.9
1.0
EBITDA €B
1.6
1.2
1.2
1.0
1.3
1.4
1.2
1.2
1.1
1.2
Income tax €B
0.2
0.0
0.1
0.1
0.2
0.2
0.1
0.0
0.2
0.2
Net income €B
0.2
0.0
0.2
0.2
0.6
0.6
0.6
0.7
0.5
0.5
EPS, diluted €
0.23
0.06
0.27
0.28
0.90
0.91
0.87
0.97
0.80
0.78
Dividend / sh €
·
·
·
·
·
·
·
·
·
·
Payout %
1
0
0
137
18
38
23
19
23
·
ROE %
2.8
0.8
3.3
3.6
12.5
13.8
15.2
18.0
14.7
·
Shares out B
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed